CMS certification 410010
Women & Infants Hospital of Rhode Island
101 Dudley Street, Providence, RI 02905
Women & Infants Hospital of Rhode Island has a CMS overall rating of 4 out of 5 stars. 71% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. Of the 11 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 1 and worse on none. Emergency patients spend a median of 3 h 54 min in its emergency department before leaving (US median 2 h 42 min).
Every figure on this page is published by CMS; we arrange and explain it, and score nothing ourselves.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: 503 completed surveys, 11% response rate, Oct 2024 – Sep 2025.
Emergency department
How long emergency patients spent here and how some time-critical care went, from CMS's timely and effective care measures, Oct 2024 – Sep 2025. CMS classes this emergency department's patient volume as medium; busier departments tend to have longer times, so the national median for departments of the same volume is shown too. These are medians over a year of visits, not a live wait time.
| Measure | This hospital | RI | US |
|---|---|---|---|
| Median time in the emergency department before leaving Lower is better · 2,345 visits sampled · US median for EDs of the same volume: 2 h 45 min | 3 h 54 min | 3 h 43 min | 2 h 42 min |
| Median time for psychiatric and mental health patients Lower is better · 14 visits sampled | 6 h 41 min | 5 h 16 min | 4 h 17 min |
| Left before being seen Lower is better · 28,225 patients | 3% | 4% | 2% |
| Severe sepsis and septic shock: all recommended care given Higher is better · 13 patients | 54% | 64% | 65% |
How Women & Infants Hospital of Rhode Island compares with nearby hospitals
The closest hospitals of the same kind that CMS rates or surveys - the same city first, then the same county and ZIP area. Every figure is CMS's: the overall star rating, the share of patients who would definitely recommend the hospital, the median time emergency patients spent before leaving, and how many death, complication, infection and readmission measures CMS found better or worse than the national rate.
| Hospital | CMS stars | Would recommend | ER median time | Vs the nation |
|---|---|---|---|---|
| Women & Infants Hospital of Rhode IslandThis hospital | 4/5 | 71% | 3 h 54 min | 1 better |
| The Miriam HospitalSame city | 4/5 | 72% | 4 h 54 min | 6 better |
| Providence VA Medical CenterSame city | 4/5 | 78% | — | 2 worse |
| Rhode Island HospitalSame city | 4/5 | 69% | 4 h 18 min | 3 better 2 worse |
| Roger Williams Medical CenterSame city | 3/5 | 60% | 3 h 32 min | 2 better |
| Our Lady of Fatima HospitalSame county · North Providence | 3/5 | 69% | 3 h 13 min | 1 better |
Hospitals differ in size and in how sick their patients are. CMS adjusts its outcome measures for that, but a star or a percentage is a starting point for questions, not a verdict. All hospitals in Providence.
Deaths
How many patients died within 30 days of admission, adjusted by CMS for how sick they were. Lower is better. Data from Jul 2022 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| All patients, hospital-wide 76 cases | Too few cases | 3.8% | 3.9% |
6 more measures had too few cases here to report.
Complications
How often patients had serious complications, most of them after surgery, adjusted for how sick they were. Lower is better. Data from Jul 2022 – Jun 2024.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Serious complications, combined measure | No different | 1 likely 0.49 – 1.5 | 1 |
| Pressure ulcers (bed sores) 123 cases | No different | 0.6 per 1,000 likely 0 per 1,000 – 1.91 per 1,000 | 0.63 per 1,000 |
| Collapsed lung caused by a procedure 171 cases | No different | 0.21 per 1,000 likely 0 per 1,000 – 0.44 per 1,000 | 0.21 per 1,000 |
| Broken bones from falls in the hospital 185 cases | No different | 0.27 per 1,000 likely 0.05 per 1,000 – 0.49 per 1,000 | 0.27 per 1,000 |
| Bleeding or hematoma after surgery 88 cases | No different | 2.29 per 1,000 likely 0.57 per 1,000 – 4 per 1,000 | 2.34 per 1,000 |
| Kidney injury needing dialysis after surgery 76 cases | No different | 1.62 per 1,000 likely 0 per 1,000 – 3.32 per 1,000 | 1.67 per 1,000 |
| Breathing failure after surgery 73 cases | No different | 8.67 per 1,000 likely 0 per 1,000 – 18.45 per 1,000 | 9.42 per 1,000 |
| Blood clots in the lungs or legs after surgery 91 cases | No different | 3.36 per 1,000 likely 0.77 per 1,000 – 5.96 per 1,000 | 3.52 per 1,000 |
| Sepsis after surgery 73 cases | No different | 5.83 per 1,000 likely 1.62 per 1,000 – 10.05 per 1,000 | 5.27 per 1,000 |
| Surgical wound splitting open 63 cases | No different | 1.74 per 1,000 likely 0.22 per 1,000 – 3.27 per 1,000 | 1.77 per 1,000 |
| Accidental cut or tear during abdominal surgery 97 cases | No different | 1.57 per 1,000 likely 0.5 per 1,000 – 2.63 per 1,000 | 1.06 per 1,000 |
2 more measures had too few cases here to report.
Infections caught in the hospital
Standardized infection ratio: 1.0 means as many infections as CMS predicted for a hospital like this one. Lower is better. Data from Oct 2024 – Sep 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Bloodstream infections from central lines (CLABSI) | No different | 0.51 likely 0.13 – 1.39 | 1 |
| Surgical site infections after abdominal hysterectomy | No different | 0 | 1 |
| MRSA bloodstream infections | No different | 1.29 likely 0.22 – 4.27 | 1 |
| C. diff intestinal infections | Better | 0 | 1 |
2 more measures had too few cases here to report.
Readmissions and return visits
How often patients had to come back to a hospital after going home. Lower is better. Data from Jul 2023 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Unplanned visits after an outpatient colonoscopy 392 cases | No different | 12.4 per 1,000 likely 9.3 per 1,000 – 16.7 per 1,000 | 13 per 1,000 |
| Hospital admissions during outpatient chemotherapy 136 cases | No different | 10.2 per 100 likely 7.4 per 100 – 13.8 per 100 | 10.7 per 100 |
| ER visits during outpatient chemotherapy 136 cases | No different | 5.9 per 100 likely 4 per 100 – 8.4 per 100 | 5.4 per 100 |
| Unplanned visits after outpatient surgery 184 cases | No different | 0.9 likely 0.6 – 1.3 | — |
10 more measures had too few cases here to report.
Clinicians registered at this address
355 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 26 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Obstetrics & Gynecology | 63 |
| Neonatal-Perinatal Medicine | 26 |
| Family | 23 |
| Advanced Practice Midwife | 16 |
| Clinical | 16 |
| Pediatrics | 16 |
| Neonatal | 15 |
| Dietitian, Registered | 14 |
| Anesthesiology | 13 |
| Anatomic Pathology & Clinical Pathology | 11 |
| Nurse Anesthetist, Certified Registered | 10 |
| Nurse Practitioner | 10 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $759,558
- 2020 $1.1M
- 2021 $1.3M
- 2022 $759,910
- 2023 $565,938
- 2024 $295,162
- 2025 $432,174
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Medical devices and supplies on long-term loan | $4,740 | 10 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Abbott Laboratories | $256,076 | 7 |
| Abbvie INC. | $79,637 | 14 |
| Genentech, Inc. | $31,037 | 10 |
| Pfizer INC. | $20,000 | 2 |
| GlaxoSmithKline, LLC. | $17,872 | 4 |
| Aadi Bioscience, Inc. | $14,020 | 7 |
| AstraZeneca Pharmaceuticals LP | $7,416 | 2 |
| Fujirebio Diagnostics, Incorporated | $2,000 | 1 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System Abbott Laboratories | $252,000 |
| A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FR-Expressing Advanced-Stage Serous Epithelial … ABBVIE INC. | $43,000 |
| Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC Genentech, Inc. | $31,037 |
| THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CANCER COMPASSHER2 RESIDUAL DIS… PFIZER INC. | $20,000 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB GlaxoSmithKline, LLC. | $15,692 |
| Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ov… ABBVIE INC. · NCT05456685 | $15,069 |
| Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO) ABBVIE INC. · NCT05041257 | $14,317 |
| Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer Aadi Bioscience, Inc. · NCT05997017 | $14,020 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Women & Infants Hospital of Rhode Island
Is Women & Infants Hospital of Rhode Island a good hospital?
Women & Infants Hospital of Rhode Island has a CMS overall rating of 4 out of 5 stars. Of the 11 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 1 and worse on none. These are hospital-wide results published by CMS; they do not rate individual doctors or departments.
Would patients recommend Women & Infants Hospital of Rhode Island?
71% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. The figure comes from 503 completed HCAHPS surveys.
How long is the wait in the Women & Infants Hospital of Rhode Island emergency room?
Emergency patients spend a median of 3 h 54 min in its emergency department before leaving (US median 2 h 42 min). Among US emergency departments with medium patient volume, like this one, the median is 2 h 45 min. 3% of emergency patients left before being seen (US 2%). These are medians over a year of visits, not a live wait time.
Does Women & Infants Hospital of Rhode Island receive money from drug and device companies?
Drug and device makers reported $432,174 in payments to Women & Infants Hospital of Rhode Island for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.